Ruxolitinib is a kinase inhibitor used to treat myelofibrosis and polycythemia vera. It works by blocking signals that promote cancer cell proliferation. Ruxolitinib is effective in managing hematological malignancies. In summary, Ruxolitinib is beneficial for treating specific blood cancers.
Ruxolitinib inhibits Janus kinases (JAK1 and JAK2), reducing signaling pathways that promote cell growth and survival in myeloproliferative disorders.



